STATs in cancer inflammation and immunity: a leading role for STAT3
- PMID: 19851315
- PMCID: PMC4856025
- DOI: 10.1038/nrc2734
STATs in cancer inflammation and immunity: a leading role for STAT3
Abstract
Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in determining whether immune responses in the tumour microenvironment promote or inhibit cancer. Persistently activated STAT3 and, to some extent, STAT5 increase tumour cell proliferation, survival and invasion while suppressing anti-tumour immunity. The persistent activation of STAT3 also mediates tumour-promoting inflammation. STAT3 has this dual role in tumour inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-kappaB (NF-kappaB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-kappaB-mediated T helper 1 anti-tumour immune responses. Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4856025/bin/nihms-779912-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4856025/bin/nihms-779912-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4856025/bin/nihms-779912-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4856025/bin/nihms-779912-f0004.gif)
Similar articles
-
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.Mol Cell Endocrinol. 2017 Aug 15;451:1-14. doi: 10.1016/j.mce.2017.05.033. Epub 2017 May 30. Mol Cell Endocrinol. 2017. PMID: 28576744 Review.
-
Stat3: linking inflammation to (gastrointestinal) tumourigenesis.Clin Exp Pharmacol Physiol. 2012 Aug;39(8):711-8. doi: 10.1111/j.1440-1681.2011.05659.x. Clin Exp Pharmacol Physiol. 2012. PMID: 22211709 Review.
-
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Drug Resist Updat. 2010. PMID: 20471303 Review.
-
IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.Exp Hematol. 2008 Feb;36(2):181-92. doi: 10.1016/j.exphem.2007.09.010. Epub 2007 Nov 26. Exp Hematol. 2008. PMID: 18023521
-
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.Nat Rev Immunol. 2007 Jan;7(1):41-51. doi: 10.1038/nri1995. Nat Rev Immunol. 2007. PMID: 17186030 Review.
Cited by
-
Exploiting bacteria for cancer immunotherapy.Nat Rev Clin Oncol. 2024 Jun 5. doi: 10.1038/s41571-024-00908-9. Online ahead of print. Nat Rev Clin Oncol. 2024. PMID: 38840029 Review.
-
Syntaxin6 contributes to hepatocellular carcinoma tumorigenesis via enhancing STAT3 phosphorylation.Cancer Cell Int. 2024 Jun 4;24(1):197. doi: 10.1186/s12935-024-03377-3. Cancer Cell Int. 2024. PMID: 38834986 Free PMC article.
-
From immune equilibrium to tumor ecodynamics.Front Oncol. 2024 May 10;14:1335533. doi: 10.3389/fonc.2024.1335533. eCollection 2024. Front Oncol. 2024. PMID: 38807760 Free PMC article.
-
Clinicopathological significance of protein disulphide isomerase A3 and phosphorylated signal transducer and activator of transcription 3 in cervical carcinoma.Contemp Oncol (Pozn). 2024;28(1):51-62. doi: 10.5114/wo.2024.139368. Epub 2024 May 3. Contemp Oncol (Pozn). 2024. PMID: 38800530 Free PMC article.
-
Inflammation and cancer: friend or foe?Front Pharmacol. 2024 May 10;15:1385479. doi: 10.3389/fphar.2024.1385479. eCollection 2024. Front Pharmacol. 2024. PMID: 38799159 Free PMC article. Review.
References
-
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. - PubMed
-
-
Catlett-Falcone R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115. This report was the first to document that IL-6–JAK–STAT3 signalling, which increases inflammation-induced cancer, is important for the growth and survival of human tumour cells.
-
-
- Bollrath J, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91–102. - PubMed
-
-
Kujawski M, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008;118:3367–3377. This study demonstrated that STAT3 is a crucial mediator for myeloid cell-induced tumour angiogenesis.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous